Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EBT: 2020-2025

Historic EBT for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to -$34.0 million.

  • Lyell Immunopharma's EBT rose 23.69% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.6 million, marking a year-over-year decrease of 71.61%. This contributed to the annual value of -$334.7 million for FY2024, which is 49.71% down from last year.
  • Lyell Immunopharma's EBT amounted to -$34.0 million in Q3 2025, which was up 22.52% from -$43.9 million recorded in Q2 2025.
  • Lyell Immunopharma's EBT's 5-year high stood at -$11.3 million during Q4 2022, with a 5-year trough of -$196.2 million in Q4 2024.
  • Its 3-year average for EBT is -$62.7 million, with a median of -$52.4 million in 2023.
  • Per our database at Business Quant, Lyell Immunopharma's EBT skyrocketed by 76.00% in 2022 and then slumped by 362.66% in 2023.
  • Lyell Immunopharma's EBT (Quarterly) stood at -$47.2 million in 2021, then spiked by 76.00% to -$11.3 million in 2022, then slumped by 362.66% to -$52.4 million in 2023, then tumbled by 274.31% to -$196.2 million in 2024, then grew by 23.69% to -$34.0 million in 2025.
  • Its EBT was -$34.0 million in Q3 2025, compared to -$43.9 million in Q2 2025 and -$53.5 million in Q1 2025.